Biomedical Research Center, Korea Institute of Science and Technology, 39-1 Haweolgog-Dong, Sungbook-Gu, Seoul 136-791, South Korea.
J Control Release. 2010 Sep 1;146(2):219-27. doi: 10.1016/j.jconrel.2010.04.004. Epub 2010 Apr 24.
Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.
治疗诊断多功能纳米粒子在疾病的同时诊断、最小毒性的靶向药物输送以及治疗监测方面具有巨大的应用潜力。癌症治疗目前面临的挑战之一是增强成像探针和抗癌药物对肿瘤的特异性靶向。本文报道了基于壳聚糖的肿瘤归巢纳米粒子（CNPs），其可同时进行癌症诊断和治疗（癌症治疗诊断）。这些 CNPs 具有稳定性好、变形能力强、能快速被肿瘤细胞摄取等三个独特特性。这些特性对于提高其肿瘤靶向特异性和降低其在正常组织中的非特异性摄取至关重要。为了将这些 CNPs 开发成新型的治疗诊断纳米粒子，我们用近红外荧光染料 Cy5.5 对其进行了标记，用于成像，并用抗癌药物紫杉醇（PTX-CNPs）进行了装载，用于癌症治疗。Cy5.5 标记的 PTX-CNPs 在 SCC7 荷瘤小鼠中表现出显著增强的肿瘤归巢能力，同时对其他组织的非特异性摄取较低。治疗诊断纳米粒子，Cy5.5 标记的 PTX-CNPs，非常适用于早期癌症的同时诊断和药物输送。
